Avid Bioservices Inc (CDMO)

[entdoc]

side-note perspective: close friend diagnosed recently with Hodgkin's lymphoma. Being treated at an excellent hematology-oncology department of an exceptional medical school by well-known and respected oncologist. When I mentioned the possibility of using Bavituximab with standard of care, and that patient was willing, he said, "I am not familiar with it". When I gave him a thumbnail sketch his non-sequiter response was, "We DO consider MABs for refractory/non-responsive cases. I repeated the Bavi spin, and the IST possibilities that (by inference) could increase his fame and cure rate...that Bavi could be added to standard of care...and...and...
Interestingly, I had similar experiences with clinical oncologists with Erbitux when that MAB was at a more advanced stae in clinical trial than Bavi. The point behind this post is that many here know much more about Bavi than most clinical oncologists. It takes time. It's monkey see/monkey do. And, "first do no harm".